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Protocol Analysis of an Antimicrobial Renal Dose Protocol
at a Large, Tertiary Medical Center
Nicole A. Hulsebus, PharmD; Meagan N. Greckel, PharmD; Brent W. Footer, PharmD, BCIDP
Background
•Infection-related morbidity and mortality remains high
among critically ill patients.
•Despite early and targeted use of antimicrobials,
adequate exposure of some agents is difficult to
accomplish.
•Regulatory requirements for renal dose adjustments are
intended for those with chronic kidney disease (CKD).
•Not studied in patients with an acute kidney injury
(AKI) or the critically ill
•A retrospective study examined prevalence of AKI in
18,000 patients and showed that renal function
recovered more often than impairment persisted.
•Overall rate of AKI on admission was 17.5%.2
•AKI resolved within 48 hours in 57.2% of patients.2
•It may be beneficial to reserve dose adjustment for
antimicrobials with a wider safety margin and fewer
toxicities (ex. beta-lactams) until AKI persists for 48
hours after.
•Critical care pharmacy in collaboration with intensivists
at the institution implemented a protocol in July 2021 as
part of continuing quality improvement to delay dose
adjustment in patients admitted to the intensive care
unit (ICU) with AKI.

Discussion
Results
Table 1. Patient Demographics and Characteristics
Characteristic
Mean age (years) ± SD
Mean weight (kg) ± SD
Mean height (cm) ± SD
Mean BMI (kg/m2) ± SD
Female (no., % of patients)
Mean baseline SCr (mg/dL) ± SD
Mean peak SCr (mg/dL) ± SD

5, 21%

2, 8%
3, 13%

IAI

UTI

CAP

4, 17%

HAP/VAP

SSTI

Other

Figure 2. Antimicrobials Prescribed by Indication

Objectives

•Institution review board (IRB)-approved
•Electronic health record (EHR)-based quasi-experimental
pre and post implementation study of those with an AKI
in the ICU at a tertiary medical center
•Inclusion criteria:
•Patients ≥18 years old
•Patients admitted to or residing in the ICU that were
admitted with or develop an AKI (SCr ≥0.3 mg/dL
from baseline)
•Received an approved antimicrobial
•Beta-lactam/beta-lactamase inhibitors,
carbapenems, cephalosporins, clindamycin,
penicillins, fluconazole
•Exclusion criteria
•Renal replacement therapy
•Intermittent HD (iHD), intraperitoneal
hemodialysis (PD), or continuous renal
replacement therapy (CRRT)
•Extracorporeal membrane oxygenation (ECMO)
•Urine output (UOP) of <0.5 mL/kg/hr in preceding
24 hours prior to assessment
•History of CKD (chart documentation of CKD Stage
3 or higher or an eGFR <60 ml/min/1.73m2 for ≥3
months
•Study period
•Pre-implementation: January 2020 to June 2021
•Post-implementation: July 2021 to November 2021

9, 37%

1, 4%

•Analyze the clinical effect of delaying antimicrobial
adjustment for the first 48 hours for patients admitted to
the ICU with an AKI or patients who developed an AKI
during their ICU stay.

Methods

Post-implementation (n=0)
0
0
0
0
0
0
0

Figure 1. Indications for Prescribed Antimicrobials
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•Primary outcome
• Number of patients receiving full dose antimicrobial
therapy for the first 48 hours of an AKI in patients that
were admitted to or reside in the ICU
•Secondary outcomes
•Mortality rate of patients with AKI in the ICU
•Time to resolution of AKI [<0.3 mg/dL increase from
baseline serum creatinine (SCr)]
•Length of stay in the ICU

Pre-implementation (n=23)
65 ± 15.9
75.6 ± 20.9
166 ± 12.5
27.5 ± 7.4
12, 52.2
0.88 ± 0.18
3.09 ± 1.41

1
1

8
6
4

3

2
1

2
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Cefepime

Meropenem

Piperacillin/Tazobactam

Table 2. Clinical Outcomes
Outcome
Pre-implementation (n=23) Post-implementation (n=0)
Number of patients receiving full-dose
3, 13.0
0
antimicrobial therapy (no., % of patients)
Mortality rate of patients with AKI in the
3, 13.0
0
ICU (no., % of patients)
AKI resolution (no., % of patients)
19, 82.6
0
Cefepime (FEP)
7, 100
0
Meropenem (MEM)
5, 100
0
Piperacillin/tazobactam (TZP)
7, 63.6
0
Time to resolution of AKI (days) ± SD
4.8 ± 2.6
0
Cefepime (FEP)
4.8 ± 3.1
0
Meropenem (MEM)
3.4 ± 1.3
0
Piperacillin/tazobactam (TZP)
5.6 ± 2.5
0
Length of stay in the ICU (days) ± SD
5.9 ± 5.0
0

Patient Population
•A total of 23 patients from 1400 total encounters met
inclusion criteria during the pre-implementation period,
with none meeting inclusion criteria after protocol
implementation in July 2021
•Collection period January 2020 through November 2021.
•Average age of 65 years, range 18-88
•Over half of patients (58.3%) with overweight or obesity
(average BMI 27.5, range 15.0-44.2)
Clinical Outcomes
•Comparison between groups on clinical outcomes could
not be conducted with only pre-implementation data
available.
•Most common indications for antimicrobial therapy were
intra-abdominal infection (IAI), urinary tract infection
(UTI), community-acquired pneumonia (CAP), hospitaland ventilator-acquired pneumonia (HAP/VAP), and skin
and soft tissue infections (SSTI)
•Others include febrile neutropenia, bacteremia, and
meningitis
•All but 3 patients in the pre-implementation period were
dose adjusted on the first day that criteria for renal dose
adjustment was met, meaning that 13.0% received fulldose antimicrobial therapy for the first 48 hours of AKI.
•There appears to be a trend with use of TZP and a longer
time to resolution of AKI (nearly 1 day longer than FEP
and 2 days longer than MEM), and all 4 patients whose
AKI did not resolve received TZP.
•Difficult to evaluate outcomes since post-implementation
period data is absent but based on the results it appears
that delaying renal dose adjustment in patients with AKI
in the ICU has low utility with how few patients qualified.
Study Limitations
•Retrospective, non-randomized design
•Select data was pulled retrospectively from EHR and
evaluated by a single reviewer.
•Unable to compare pre- and post-implementation of the
protocol as no patients met inclusion criteria during the
post-implementation data collection period.
•The protocol was implemented with the assumption that
providers would utilize the sepsis order set, which
includes cefepime.
•There was rare use of the sepsis order set, TZP was
overwhelmingly the most prescribed antimicrobial
included in the protocol.
•The presence of COVID-19 during the data collection
period led to many patients being excluded from the
protocol due to ECMO or renal replacement therapy
needs.
•The strict protocol led to many patients being excluded
based on inadequate UOP, baseline CKD, and renal
replacement therapy.

Going Forward
•May be worthwhile to collect data again for this protocol
as the impact of COVID-19 lessens, particularly if
cefepime is prescribed more often.
•The potential increased risk of slowed or lack of recovery
from AKI with TZP could warrant further investigation.
•Overall, our use of a strict protocol and inclusion of very
few cases may not make this protocol worthwhile to
implement.
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